The information about the mutational status of SF3B1 has not only allowed the redefinition of the diagnostic criteria in MDS but also the improvement of the risk stratification, identifying new sub-categories: MDS-SF3B1 and MDS/MPN with SF3B1 mutation and thrombocytosis. Here, SF3B1 is linked to myeloproliferative disorder.